High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.

BACKGROUND Although radiotherapy remains the main postoperative treatment for patients with malignant glioma, modifications to regimens have not improved the poor outlook of patients with this disease. We aimed to investigate whether high-dose conformal radiotherapy improves the survival of patients with supratentorial malignant glioma compared with conventional radiotherapy. METHODS 29 patients with anaplastic astrocytoma and 61 patients with glioblastoma who received high-dose conformal radiotherapy during 1990-2002 were compared with 34 patients with anaplastic astrocytoma and 60 patients with glioblastoma who received conventional 60 Gy radiotherapy during 1979-89. 77 of the 90 patients receiving high-dose radiotherapy were given 80 Gy; the remaining 13 patients, all with glioblastoma, received 90 Gy. Radiotherapy was planned on the basis of images taken before surgery, and doses were delivered in 2 Gy per fraction per day for 5 days a week. Hazard ratios for death were calculated with a Cox model, and were adjusted for age, Karnofsky performance scale, tumour size, and extent of resection. FINDINGS Patients who received high-dose radiotherapy had significantly longer overall survival compared with those who received conventional radiotherapy (adjusted hazard ratio 0.30 [95% CI 0.12-0.76], p=0.011 for anaplastic astrocytoma and 0.49 [0.28-0.87], p=0.014 for glioblastoma). Patients with anaplastic astrocytoma in the high-dose group have not yet reached median survival; median survival in the conventional radiotherapy group was 22.3 months (95% CI 20.6-24.0). 5-year survival was 51.3% (29.2-73.4) for the high-dose group and 14.7% (0.0-30.0) for the conventional group. Median survival in patients with glioblastoma was 16.2 months (12.8-19.6) for the high-dose group and 12.4 months (10.0-14.8) for the conventional group. 2-year survival was 38.4% (23.5-53.3) for the high-dose group and 11.4% (0.0-25.3) for the conventional group. Survival did not differ between those that received 80 Gy radiotherapy and those that received 90 Gy (hazard ratio 0.94 [95% CI 0.42-2.12]). The higher frequency of radiation-induced white matter abnormality in the high-dose group compared with the conventional radiotherapy group did not lead to increased disability. INTERPRETATION High-dose, standard-fractionated radiotherapy shows potential as the main postoperative treatment for patients with supratentorial malignant glioma.

[1]  W. Curran,et al.  Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. , 2000, International Journal of Radiation Oncology, Biology, Physics.

[2]  Susan M. Chang,et al.  Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.

[3]  W. Powlis,et al.  Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. , 1993, International journal of radiation oncology, biology, physics.

[4]  M. Martel,et al.  Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. , 1999, International journal of radiation oncology, biology, physics.

[5]  P. Rubin,et al.  High dose radiation therapy in the treatment of malignant gliomas: final report. , 1979, International journal of radiation oncology, biology, physics.

[6]  F. Mornex,et al.  Radiation therapy for malignant astrocytomas in adults. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  E. B. Butler,et al.  Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[8]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[9]  Christopher Nimsky,et al.  Proton Magnetic Resonance Spectroscopic Imaging Integrated into Image-guided Surgery: Correlation to Standard Magnetic Resonance Imaging and Tumor Cell Density , 2005, Neurosurgery.

[10]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[11]  M. Prados,et al.  Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Misailidou,et al.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Nelson,et al.  White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02) , 1994, Cancer.

[15]  V. Strand,et al.  Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. , 2001, The Journal of rheumatology.

[16]  A. Friedman,et al.  Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography , 1991, Annals of neurology.

[17]  G. Pilkington,et al.  Molecular and cellular pathology of intrinsic brain tumours , 1997, Cancer and Metastasis Reviews.

[18]  Adam Dicker,et al.  The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. , 2004, International journal of radiation oncology, biology, physics.

[19]  K. Nakagawa,et al.  An integrated radiotherapy treatment system and its clinical application. , 1987, Radiation medicine.

[20]  Maria Werner-Wasik,et al.  Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. , 2004, International journal of radiation oncology, biology, physics.

[21]  J. O'fallon,et al.  Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Taenzer,et al.  Acute Effects on Neuropsychological Function and Quality of Life by High‐Dose Multiple Daily Fractionated Radiotherapy for Malignant Astrocytomas: Assessing the Tolerability of a New Radiotherapy Regimen , 1997, Psycho-oncology.

[23]  N. Laperriere,et al.  Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  K. Sultanem,et al.  The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. , 2004, International journal of radiation oncology, biology, physics.

[25]  H. Bartelink,et al.  European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. , 1988, Frontiers of radiation therapy and oncology.

[26]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[27]  D. Nelson,et al.  Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02 , 1996, Cancer.

[28]  N. Bleehen,et al.  A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.

[29]  M. Westphal,et al.  Glioma invasion in the central nervous system. , 1996, Neurosurgery.

[30]  K. Takakura,et al.  Effects of ACNU and radiotherapy on malignant glioma. , 1986, Journal of neurosurgery.

[31]  S. Piantadosi,et al.  Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Benedick A Fraass,et al.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Y. Katayama,et al.  Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas , 2005, Journal of Neuro-Oncology.

[34]  W. Simpson,et al.  Fractionation study in the treatment of glioblastoma multiforme. , 1976, International journal of radiation oncology, biology, physics.

[35]  K. Nakagawa,et al.  High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. , 1998, International journal of radiation oncology, biology, physics.

[36]  M. Piérart,et al.  Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Walker,et al.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.

[38]  P. Wen,et al.  Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. , 1999, Journal of neurosurgery.

[39]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.